| Agent | Brand name | Dosing |
| Arformoterol | Brovana (United States) | Solution for nebulization: Inhale contents of 1 vial (15 mcg/2 mL) twice daily via standard jet nebulizer¶ |
| FormoterolΔ | Perforomist (United States) | Solution for nebulization: Inhale contents of 1 vial (20 mcg/2 mL) twice daily via standard jet nebulizer¶ |
| Foradil (Canada) | DPI:◊ Inhale contents of 1 capsule (12 mcg/capsule) twice daily§ | |
| Oxeze Turbuhaler (Canada: 6 mcg/inhalation and 12 mcg/inhalation)¥ | DPI: 1 to 2 inhalations (12 to 24 mcg total dose) twice daily | |
| Indacaterol‡ | Arcapta Neohaler† | DPI:◊ Inhale contents of 1 capsule (75 mcg/capsule) once daily |
| Onbrez Breezhaler (Canada) | DPI:◊ Inhale contents of 1 capsule (75 mcg/capsule) once daily | |
| Olodaterol | Striverdi Respimat (United States) | SMI: 2 inhalations (2.5 mcg/actuation) once daily |
| Salmeterol | Serevent Diskus (United States/Canada) | DPI:◊ 1 inhalation (50 mcg/actuation) twice daily |
COPD: chronic obstructive pulmonary disease; DPI: dry powder inhaler; SMI: soft mist inhaler.
* Vilanterol is not available as a single agent. Refer to relevant clinical topics and Lexicomp drug monographs included within UpToDate for information about combination inhalers containing vilanterol with a long-acting muscarinic antagonist and/or inhaled glucocorticoid.
¶ Data about mixing nebulized medications are limited; refer to the UpToDate topic on delivery of inhaled medications, table on mixing nebulized medications, and Lexicomp drug information monographs included within UpToDate.
Δ Formoterol is not available as a single agent inhaler in the United States. Refer to relevant clinical topics and Lexicomp drug monographs included within UpToDate for information about combination inhalers containing formoterol with a long-acting muscarinic antagonist and/or inhaled glucocorticoid.
◊ DPIs contain lactose and may contain milk protein, which may put patients with milk protein allergy at risk.
§ According to Canadian labelling, the formoterol dose can be increased to 2 capsules (24 mcg/dose) inhaled twice daily (maximum dose 48 mcg/day), if needed for symptom control.
¥ Oxeze Turbuhaler has been approval in Canada for use in asthma but not COPD.
‡ In countries outside the United States and Canada, indacaterol doses of 150 or 300 mcg/day have been approved and are available.
† Arcapta Neohaler is no longer available in the United States, but may be available elsewhere.
